10-Q quarterly report · filed Nov 5, 2026

Verastem, Inc. (VSTM) Q3 2026 10-Q Quarterly Report

Short answer

Verastem, Inc. (VSTM) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24M (up 113.6% year over year) with net income of −$75M.

Q3 2026 key financials · XBRL

Revenue
$24M
+113.6% YoY · −40.1% QoQ
Net income
−$75M
+24.2% YoY · −115.5% QoQ
Operating margin
-313.3%
EPS (diluted)
−$0.74
+43.9% YoY · −111.4% QoQ

Source: XBRL data from the Verastem, Inc. (VSTM) Q3 2026 10-Q on SEC EDGAR. USD.

Verastem, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $24.0M, up 114% YoY from $11.2M, driven by AVMAPKI FAKZYNJA CO-PACK shipments
  • Product gross margin 84.7% vs 85.1% YoY, based on revenue and product cost figures
  • Best growth: VS-7375 clinical R&D $25.9M, up 1891% from $1.3M
  • Cash, equivalents and investments $172.8M; operating cash outflow $129.6M vs $107.6M YoY
  • Near-term funding through October 2026 offering, expected product revenue and existing resources; FDA blister-pack decision by February 7, 2027

Risk Factors

  • No material risk-factor changes identified, with the 10-Q directing investors to the 2025 Form 10-K
  • Cash burn risk: operating cash use increased to $129.6 million from $107.6 million
  • Debt interest-rate risk: $75.0 million of Initial Notes carry floating-rate interest
  • Market risk: $172.8 million held in cash, equivalents and investments exposed to interest-rate changes
  • Foreign-currency risk: CRO and manufacturer contracts may be denominated in foreign currencies

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Verastem, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.